GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Telo Genomics Corp (TSXV:TELO) » Definitions » Buyback Yield %

Telo Genomics (TSXV:TELO) Buyback Yield % : 0.00 (As of May. 01, 2025)


View and export this data going back to 2012. Start your Free Trial

What is Telo Genomics Buyback Yield %?

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

Telo Genomics's current buyback yield was 0.00%.


Telo Genomics Buyback Yield % Historical Data

The historical data trend for Telo Genomics's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Telo Genomics Buyback Yield % Chart

Telo Genomics Annual Data
Trend Dec14 Dec15 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Buyback Yield %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -17.52 -7.54 -0.92 -13.50 -4.71

Telo Genomics Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Buyback Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - -4.71 - -

Competitive Comparison of Telo Genomics's Buyback Yield %

For the Diagnostics & Research subindustry, Telo Genomics's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Telo Genomics's Buyback Yield % Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Telo Genomics's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where Telo Genomics's Buyback Yield % falls into.


;
;

Telo Genomics Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

Telo Genomics's Buyback Yield for the fiscal year that ended in Jun. 2024 is calculated as

Buyback Yield=Net Issuance of Stock / Market Cap
=- (Repurchase of Stock + Issuance of Stock) / Market Cap
=- (0 + 0.65) / 13.7936
=-4.71%

Telo Genomics's annualized Buyback Yield for the quarter that ended in Dec. 2024 is calculated as

Buyback Yield=Net Issuance of Stock(TTM) / Market Cap
=- (Repurchase of Stock + Issuance of Stock) (TTM)** / Market Cap
=- (0 + 0) / 13.00247
=0.00%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** If the quarter corresponds to the year-end period, we will use the annual Repurchase of Stock and Issuance of Stock data .


Telo Genomics Buyback Yield % Related Terms

Thank you for viewing the detailed overview of Telo Genomics's Buyback Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


Telo Genomics Business Description

Traded in Other Exchanges
Address
101 College Street, Suite 200, MaRS Centre, South Tower, Toronto, ON, CAN, M5G 1L7
Telo Genomics Corp is a personalized medicine company. The company through its wholly-owned subsidiary is engaged in developing diagnostic and prognostic products that may save lives, improve the quality of life, and reduce the cost of care associated with numerous diseases that display genomic instability. The company has a single operating segment, focused on the development and commercialization of predictive technological products designed to personalize treatment plans for patients who have specific conditions.
Executives
Kristan Joseph Weinberg Senior Officer
William John Meekison Director
Hugh Rogers Director

Telo Genomics Headlines

From GuruFocus